Purple Biotech Ltd.
PPBT | TA
Overview
Corporate Details
- ISIN(s):
- IL0007650166
- LEI:
- Country:
- Israel
- Address:
- Oppenheimer 4, 7670104 Rehovot
- Website:
- https://purple-biotech.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company's core focus is on overcoming tumor immune evasion and drug resistance by targeting the tumor microenvironment (TME). Its pipeline features innovative treatments designed to provide effective and durable therapeutic outcomes. Formerly known as Kitov Pharma Ltd., Purple Biotech actively expands its portfolio, including through the acquisition of Immunorizon and its portfolio of tri-specific antibodies, to advance its mission of developing novel oncology treatments.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Purple Biotech Ltd..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-06 16:10 |
Foreign Filer Report
Purple Biotech Reports Second Quarter 2025 Financial Results
|
English | 275.0 KB | |
| 2025-08-06 16:10 |
Foreign Filer Report
Purple Biotech Reports Second Quarter 2025 Financial Results
|
English | 36.9 KB | |
| 2025-07-23 16:11 |
Foreign Filer Report
6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Prog…
|
English | 196.4 KB | |
| 2025-07-23 16:11 |
Foreign Filer Report
6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Prog…
|
English | 36.8 KB | |
| 2025-06-23 16:18 |
Foreign Filer Report
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAP…
|
English | 191.8 KB | |
| 2025-06-23 16:18 |
Foreign Filer Report
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAP…
|
English | 36.9 KB | |
| 2025-06-17 17:08 |
Foreign Filer Report
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients w…
|
English | 214.2 KB | |
| 2025-06-17 17:08 |
Foreign Filer Report
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients w…
|
English | 36.8 KB | |
| 2025-06-04 16:12 |
Regulatory News Service
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Pla…
|
English | 156.4 KB | |
| 2025-06-04 16:12 |
Registration Form
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Pla…
|
English | 36.6 KB | |
| 2025-05-21 16:22 |
Foreign Filer Report
Purple Biotech Reports First Quarter 2025 Financial Results
|
English | 219.5 KB | |
| 2025-05-21 16:22 |
Foreign Filer Report
Purple Biotech Reports First Quarter 2025 Financial Results
|
English | 36.8 KB | |
| 2025-05-12 16:39 |
Foreign Filer Report
6K: Purple Biotech Appoints Shai Lankry as Chief Financial Officer
|
English | 175.6 KB | |
| 2025-05-12 16:39 |
Foreign Filer Report
6K: Purple Biotech Appoints Shai Lankry as Chief Financial Officer
|
English | 36.6 KB | |
| 2025-05-07 01:45 |
Investor Presentation
6K: Purple Biotech Corporate Presentation May 2025
|
English | 30.7 MB |
Automate Your Workflow. Get a real-time feed of all Purple Biotech Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Purple Biotech Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
